Physician profile
Corwin Mcgee
NPI 1447783261
$4,528.82
in general payments reported to CMS, 2019-2025
27 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $749 · 2024: $2,155 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,528.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,210.14 | 2023-2025 | Enbrel, Otezla, Krystexxa |
| Abbvie INC. | $758.28 | 2023-2025 | |
| Janssen Biotech, INC. | $292.89 | 2023-2025 | Tremfya, Simponi Aria |
| Glaxosmithkline, LLC. | $250.92 | 2023-2024 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $219.41 | 2023-2025 | Saphnelo |
| Ucb, INC. | $205.16 | 2023-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $164.71 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.34 | 2023-2024 | Ofev, Cyltezo |
| Lilly USA, LLC | $134.08 | 2023-2025 | Taltz, Zepbound |
| Mallinckrodt Hospital Products INC. | $127.91 | 2024-2025 | Acthar |
| Genzyme Corporation | $107.77 | 2024-2025 | |
| Octapharma USA, INC. | $107.33 | 2023 | Octagam Immune Globulin (Human) |
| Radius Health, INC. | $103.32 | 2023-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $93.02 | 2024-2025 | Orencia |
| Fresenius Kabi USA, LLC | $78.59 | 2023-2025 | Idacio |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $71.28 | 2024 | Purified Cortrophin Gel |
| Genentech USA, INC. | $62.10 | 2024-2025 | Actemra |
| Organon LLC | $60.73 | 2023-2025 | Hadlima |
| Aurinia Pharma U.S., INC. | $57.03 | 2024-2025 | Lupkynis |
| Sandoz INC. | $48.26 | 2024-2025 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $46.67 | 2024 | |
| Pfizer INC. | $43.88 | 2024-2025 | |
| Almatica Pharma LLC | $34.92 | 2024 | Teriparatide |
| Depuy Synthes Sales INC. | $30.19 | 2024-2025 | Orthovisc, Monovisc |
| Sobi, INC | $20.27 | 2023 | |
| Celgene Corporation | $20.20 | 2024 | Orencia |
| Avanos Medical | $19.42 | 2025 | Genvisc 850 Sodium Hyaluronate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corwin Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.